Silvio Inderbitzin

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland.

Nexilis AG is a Swiss medtech company that specializes in providing cost-effective fixation enhancement for any bone screw. The private company's flagship product is the Immediate Stabilisation System (ISS), which is an implantable polymer sleeve that is moulded around the pedicle screw using ultrasonic energy. Nexilis has a culture built around innovative science, precision, and quality, and has engaged in collaborations with renowned institutions to create safe and easy-to-implement solutions for surgeons. The company was founded by Martin Horst and the CEO is Leanna Caron.

Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland.

Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland.

Nexilis AG is a Swiss medtech company that specializes in providing cost-effective fixation enhancement for any bone screw. The private company's flagship product is the Immediate Stabilisation System (ISS), which is an implantable polymer sleeve that is moulded around the pedicle screw using ultrasonic energy. Nexilis has a culture built around innovative science, precision, and quality, and has engaged in collaborations with renowned institutions to create safe and easy-to-implement solutions for surgeons. The company was founded by Martin Horst and the CEO is Leanna Caron.

Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022.

Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland.

Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland.

Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland.

Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022.

Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022.

Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022.

Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland.

Hänseler AG manufactures and wholesales pharmaceutical products. It offers liquid, semi-solid and solid drug forms and drug substances in conformity with GMP. The firm manufactures galenical, which includes liquid, semi-solid and solid drug forms; and liquid extracts and tinctures. The company was founded by Edwin Hanseler in 1975 and is headquartered in Herisau, Switzerland.

Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland.

Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland.

Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland.

Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland.